India’s Pharma and Life Sciences Innovation Opportunity
India’s pharmaceutical and life sciences sector stands at a defining inflection point. For decades, India has led on scale — the world’s third-largest producer of medicines by volume, serving close to 40% of US generics demand and producing roughly 60% of the world’s vaccines. Today, a quieter and more consequential shift is underway: from scale to science. “Built on Scale, Turning to Science,” developed jointly by BCG and HealthKois, maps India’s pharma and life sciences innovation landscape with both rigor and realism.
The report finds that green shoots of innovation are now measurable, not anecdotal. Over the past decade, more than 10 novel drug assets have originated from India — spanning first-in-class NCEs, indigenous CAR-T therapies, and AI-discovered molecules. PE/VC investment has grown ~2.1x to $731Mn in FY26, biotech startups have risen ~1.6x to ~2,400, and pharma patent filings are up more than 4x. Crucially, the shift is qualitative: Indian companies are moving beyond generics and biosimilars to originate, license, and compete globally.
This momentum is being supported by a full-stack innovation engine taking shape across four converging enablers — ~$5.0Bn in government funding, strengthening academia–industry linkages, an evolving regulatory framework, and shared R&D and manufacturing infrastructure. Indian innovators are pursuing multiple pathways to value, from late-stage in-licensing and India-first validation to global-first out-licensing and academic spin-outs — evidenced by landmark deals such as Glenmark’s $700Mn licensing agreement with AbbVie and ImmunoACT’s NexCAR19, India’s first indigenous CAR-T therapy.
Yet India’s right to win is concentrated, not universal — strongest in cost-disruptive innovation, India-specific biology and data, and science-driven platforms. Realizing the full opportunity will require closing structural gaps in patient capital, bench-to-bedside translation, clinical trial and regulatory capacity, and domestic supply chains. The next five years will determine whether India becomes a global innovation originator or remains a sophisticated development hub. This report offers a roadmap for the ecosystem — across industry, academia, investors, and policymakers — to translate potential into global leadership.